Last updated: June 18, 2018

Product lineup resulting from J&J’s $30 billion Actelion deal

Johnson & Johnson will buy Actelion , Europe’s biggest biotech company, in a $ 30 billion deal that will also carve out a listed biopharmaceutical development company run by Actelion Chief Executive Jean-Paul Clozel. Actelion’s drugs to treat pulmonary arterial hypertension (PAH) – the deadly buildup of pressure in the vessels carrying blood from the heart to the lungs – all go to J&J, but the transaction divides up other drugs Actelion is developing. As part of the transaction, J&J also gets an option on ACT-132577, a version of Opsumit within the new R&D company being developed for resistant hypertension and now in phase 2 clinical development.
Yahoo News – Top Stories

Keywords: , , , , , , ,

Readers Comments (0)

Sorry, comments are closed on this post.

Recent Posts

Have You Read?

Video News